The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of predictive and prognostic impact of molecular subtypes and central grade regarding taxane-based therapy in intermediate-risk breast cancer: Results from the EC-Doc trial.
U. Nitz
Honoraria - Amgen; Sanofi
Other Remuneration - Amgen; Sanofi
O. Gluz
Honoraria - Sanofi
C. Liedtke
Honoraria - Sanofi
Other Remuneration - Sanofi
J. B. Huober
Consultant or Advisory Role - Amgen; Sanofi
Honoraria - Amgen; Sanofi
A. Hartmann
No relevant relationships to disclose
R. E. Kates
No relevant relationships to disclose
H. H. Kreipe
No relevant relationships to disclose
E. Pelz
No relevant relationships to disclose
W. Kuhn
No relevant relationships to disclose
N. Harbeck
Honoraria - Amgen; Sanofi
Other Remuneration - Amgen; Sanofi